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 Objective:  Post-traumatic epilepsy (PTE) is a significant complication following traumatic 
brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We 
hypothesized that TBI-induced inflammation likely contributes to seizure development. We 
assessed whether genetic variation in the IL-1β gene, Il-1β levels in cerebral spinal fluid (CSF) 
and serum, and CSF/serum IL-1β ratios would predict PTE development post-TBI.  
Methods:  We investigated PTE development in 256 Caucasian adults with moderate to severe 
TBI. IL-1β tagging and functional single nucleotide polymorphisms (SNPs) were genotyped.  
Genetic variance and PTE development were assessed.  Serum and CSF IL-1β levels were 
collected from a subset of subjects (n=59) during first week post injury and evaluated for their 
associations with IL-1β gene variants and also PTE.  Temporally matched CSF/serum IL-1β 
ratios were also generated to reflect the relative contribution of serum IL-1β to CSF IL-1β.  
Results:  Multivariate analysis showed that higher CSF/serum IL-1β ratios were associated with 
increased risk for PTE over time (p=0.008). Multivariate analysis for rs1143634 revealed an 
association between the CT genotype and increased PTE risk over time (p=0.005). The CT 
genotype group also had lower serum IL-1β levels (p=0.014) and higher IL-1β CSF/serum ratios 
(p=0.093).  
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Significance:  This is the first report implicating IL-1β gene variability with PTE risk and 
linking 1) IL-1β gene variation with serum IL-1β levels observed after TBI and 2) IL-1β ratios 
with PTE risk.  Given these findings, we propose that genetic and IL-1β ratio associations with 
PTE may be attributable to biological variability with blood brain barrier integrity during TBI 
recovery. These results provide a rationale for further studies 1) validating the impact of genetic 
variability on IL-1β production after TBI, 2) assessing genetically mediated signaling 
mechanisms that contribute to IL-1β CSF/serum associations with PTE, and 3) evaluating 
targeted IL-1β therapies that reduce PTE.   
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1.0  INTRODUCTION 
Post-traumatic epilepsy (PTE) accounts for 20% of symptomatic seizures and 5% of all seizures 
in the general population.1 For those with penetrating head injury, subdural hematoma (SDH), or 
depressed skull fracture, more than 20% develop PTE.2 Time to first seizure varies greatly, with 
clinical onset reported more than 10 years post injury.3 PTE is associated with increased 
mortality, and death at a younger age, compared to patients without PTE.4 Those with PTE also 
are at a significant disadvantage regarding physical, cognitive and psychosocial issues that 
adversely impact outcome.5  Despite evidence against effective PTE prevention treatments,6 
people with TBI frequently receive long-term anticonvulsant therapy, often resulting in 
unwanted side effects and regular monitoring. Thus, identifying reliable biomarkers for 
epileptogenesis and PTE risk prognostication could have broad clinical implications on TBI 
treatment and recovery. 
Increasing evidence implicates glial cell activation and subsequent cytokine production 
following acute seizures as an important contributor to epileptogenesis.7, 8 Interestingly, a similar 
glial cell and cytokine response is also observed following TBI. One of the most widely studied 
biomarkers for epileptogenesis is interleukin-1beta (IL-1β). IL-1β is a pro-inflammatory cytokine 
produced in the central nervous system (CNS) by activated microglia and astrocytes, as well as 
in the periphery by macrophages and other immune cells. Following TBI injured tissue increases 
extracellular adenosine triphosphate which mediates CNS microglia activation9 as well as IL-1β 
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processing and release.10 Previous studies have reported increased IL-1β production,11 
microgliosis,12 and cell death up to a year following TBI,13 suggesting that IL-1β may be a useful 
marker of chronic inflammation that facilitates and perpetuates PTE risk.  
Increased IL-1β production following TBI increases CNS hyperexcitability and 
excitotoxicity through Ca2+, glutamatergic, and GABAergic mechanisms potentially 
contributing to epileptogenesis.14 Interestingly, exogenous IL-1β administration increases seizure 
activity induced by various pro-convulsant drugs in rodent models.15 Furthermore, disruption of 
the IL-1β biosynthesis pathway, with IL-1β converting enzyme (ICE/Caspase-1) inhibitors, 
results in delayed onset time and frequency of chemically induced seizures.16 Studies 
investigating plasma and cerebrospinal fluid (CSF) IL-1β levels in populations with febrile 
seizures (FS) and TLE have shown mixed results17,18 but do implicate IL-1β with the pathology. 
However, no studies have assessed IL-1β levels in association with the evolution of 
epileptogenesis and PTE risk following TBI.  
Genetic variant associations with epilepsy are another viable biomarker path for 
predicting PTE development. Previous studies have identified multiple single nucleotide 
polymorphisms (SNPs) associated with increased seizure risk following TBI.19,20 The gene 
coding for IL-1β (IL-1B) is located in the 2q12-13 region on the long arm of chromosome 2. One 
commonly studied IL-1B SNP, rs16944, located at position -511 within the promoter region, 
reportedly increases susceptibility to common types of TLE.21 Interestingly, variation within this 
same SNP increases lipopolysaccharide (LPS) induced IL-1β production 2-3 fold.22 Based on the 
known role of IL-1β in inflammation and risk for non-traumatic epilepsy, the goal of this study 
was to determine if genetic variability within the IL-1B gene and IL-1β biomarker profiles in 
CSF relative to serum  in a TBI population were associated with PTE risk.  
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2.0  METHODS 
2.1 STUDY DESIGN AND SUBJECTS 
This study was approved by the Institutional Review Board at the University of 
Pittsburgh, using an IRB approved consenting process. There were 354 subjects screened for this 
study at a single academic medical center as a part of a larger study evaluating genetics and 
biomarkers on outcomes for individuals with TBI. Based on allelic frequency information 
obtained from the database of Single Nucleotide Polymorphisms (dbSNP: 
http://www.ncbi.nlm.nih.gov/snp), this longitudinal retrospective cohort study was limited to 
Caucasians, and 32 subjects were excluded from the analysis. Subjects were 18-70 years old, had 
moderate to severe TBI (Glasgow Coma Score (GCS) ≤ 12), positive computed tomography 
(CT) scan confirming intracranial injury (TBI), and no history of premorbid seizures. 13 subjects 
had GCS>12, but were included in the moderate TBI category based on positive CT findings. Six 
subjects screened had premorbid seizures and were excluded. The remaining (n=316) subjects 
who met the race, age, medical history, and injury criteria for inclusion were further screened 
based on our criteria for PTE analysis.  
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2.1.1 IL-1β Genetic Population 
Time to first seizure was our primary variable of interest, and the cohort was further restricted to 
approximate the standard criteria for PTE.23 PTE was defined as the time to first seizure 
occurring beyond the first week post-injury. Therefore, individuals who had their first seizure 
during the first week post-injury (n=20) or died within the first week post-injury (n=40) were 
excluded. Three deceased individuals had documented history of PTE prior to death and were 
included in the analysis. This final cohort consisted of n=256 subjects. The time-course for PTE 
development can vary based on mortality status and affect genetic relationships with PTE status 
and time to first seizure. In addition to Kaplan-Meier (KM) approaches for assessing time to first 
seizure, mortality status was handled in bivariate categorical analysis by removing subjects who 
died after the first week post-injury but did not seize, leaving n=206 survivors. Time to mortality 
was handled in multivariate models using Cox Regression (see statistical approach).  
 
2.1.2 IL-1β Level Population 
This group included subjects (n=59) from the IL-1β genetics population that had ≥2 temporally 
matched CSF and serum samples available during the first week post-injury for IL-1β 
quantification (n=143 for serum and CSF samples). Similar to the IL-1β genetics cohort, subjects 
who died after the first week but did not seize were removed, leaving (n=46) survivors from 
which to analyze bivariate IL-1β associations with PTE. Time to mortality was adjusted in 
associated multivariate population analyses.  
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Serum and CSF IL-1β levels for healthy adult control subjects were also evaluated. CSF 
was obtained via lumbar puncture (n=13), and serum was obtained by venipuncture (n=11) from 
healthy control subjects. Control subjects were between, 19-60 years old, with no past or current 
bleeding disorder, brain injury, or neurological disease.  Women currently pregnant, or taking 
oral contraceptives or hormone replacement therapy, were excluded.   
2.2 CRITICAL CARE MANAGEMENT OF SEVERE TBI 
Subjects evaluated were admitted to the neurotrauma intensive care unit over a 10 year period 
and treated in accordance with the Guidelines for the Management of Severe Head Injury.24 
Standard treatment included initial extra-ventricular drain placement, central venous, and arterial 
catheters. Surgical intervention for mass lesion decompression was performed when clinically 
necessary. Intermittent electroencephalography (EEG) was used to evaluate patients with clinical 
suspicion of epileptic activity. In accordance with previously published studies, patients with 
severe TBI were typically prescribed PTE prophylaxis for the first week post-injury.25 
 
2.3 DEMOGRAPHICS AND INJURY DATA 
Patient demographic variables, including age and gender were recorded. Medical records and 
UPMC trauma registry data were reviewed to abstract clinical information regarding GCS 
scores, injury mechanism, depressed skull fracture, subdural hematoma (SDH), injury severity 
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score (ISS), isolated head injury status (IHI), and length of hospital stay. The highest GCS score 
in the first 24 hours post-injury was recorded. Depressed skull fracture and/or SDH were 
identified based on radiographic reports. Information regarding anti-epileptic drugs (AEDs) use 
was recorded only if noted in the medical records as used for seizure prophylaxis or treatment.  
ISS and IHI were determined based on the Abbreviated Injury Scale (AIS) scoring 
system, which determines severity of a specific injury based on the survivability of that injury.26  
The AIS categorizes injury to a body region from 1-6, with 6 representing the highest chance of 
an injury being lethal. ISS, a measure of global anatomical injury severity, is defined as the sum 
of squares of scores from the three most severely affected body regions.27 IHI status was based 
on the head AIS score, with ≥3 being considered a severe TBI. All subjects had a head AIS ≥3. 
Isolated TBI (IHI) was defined as head AIS ≥3 in patients with AIS <3 for each of the three most 
injured extra-cranial body regions. Non-isolated TBI was defined as head AIS score ≥3, and an 
AIS score of ≥3 for at least one extra-cranial body region.28  
2.4 SEIZURE ASSESSMENT 
Electronic medical records were reviewed for information about PTE, and time to first seizure. 
PTE determinations were abstracted from patient history and physical, ambulance, emergency 
room, and EEG reports as well as discharge/transfer summaries and inpatient/outpatient progress 
notes. Any mention of seizures, convulsions, or status epilepticus occurring after the first week 
post-injury was considered as evidence of PTE.  PTE follow-up was censored to three years post-
injury since all subjects had complete ascertainment of PTE status during this period. There was 
 6 
no difference in EEG procurement between subjects included in this study and normal standard 
of care. 
2.5 DNA EXTRACTION, SNP SELECTION, AND GENOTYPING 
DNA was extracted from one of two sources for each subject, whole blood or CSF. Whole blood 
was collected into ethylenediaminetetraacetic acid (EDTA) vacutainer tubes, processed to 
retrieve the buffy coat, and DNA was extracted using a simple salting-out procedure.29 CSF was 
collected by passive drainage, and DNA was extracted from white blood cells using Qiamp DNA 
extraction protocol for extraction from body fluids (Qiagen Corporation). Tagging SNPs 
rs1143633, rs1143634, rs3136558 with a minor allele frequency of at least 20% were selected 
based on data from the HapMap database (International HapMap Project: 
http://hapmap.ncbi.nlm.nih.gov/) and SNP database (dbSNP: 
http://www.ncbi.nlm.nih.gov/projects/SNP). These tSNPs captured the variability of the gene, 
including 1000 bases 5’ upstream into the promoter region, based on data from build 36. 
Rs1143634 is also considered a functional SNP.  Furthermore, functional SNPs rs1143627 and 
rs16944 were also selected for genotyping. 
Genotyping was completed using TaqMan allele discrimination technology and 
commercially available 5’ exonuclease Assay-on-Demand TaqMan assays (Applied Biosystems 
Incorporated). Amplification and genotype assignments were conducted using the AB17000 and 
SDS 2.0 software (Applied Biosystems). Double-masked genotype assignments were made for 
each SNP, and each discrepancy was addressed using raw data or re-genotyping. Hardy-
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Weinberg equilibrium was verified for all SNPs, indicating genotype distributions were within 
the expected proportions. Call rates for each SNP were >95%. 
2.6 CSF AND SERUM IL-1Β COLLECTION AND QUANTIFICATION 
CSF samples were collected up to every 12 hours for the first six days post-injury, and serum 
was collected daily. CSF samples were taken from an extraventricular drain (EVD) collection 
bag and blood samples via peripheral venipuncture. Collected samples were then centrifuged, 
aliquoted, and stored at -80°C until assay. A LuminexTM bead array assay (Millipore; Milliplex 
High Sensitivity 9plex) was used to measure IL-1β levels in CSF and serum. IL-1β levels were 
measured in available CSF and serum samples. Coefficients of variance for IL-1β assessments 
were <10%. 
2.7 STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS version 20.0 (Chicago, IL) and SAS (Cary, NC). 
Summary statistics included means, medians, frequencies, and standard error of the mean (SEM). 
Independent t-test, or Mann-Whitney when appropriate, was used to assess differences between 
PTE groups and continuous variables. Chi-square analysis, using Fisher’s exact test when 
appropriate, was used to assess differences between PTE and categorical variables, including IL-
1β SNP genotypes.  
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To analyze serum and CSF IL-1β levels in the context of PTE, weekly averages were 
calculated based on daily IL-1β levels for the first week post-injury. Daily values >3 standard 
deviations above/below the population mean were considered outliers and excluded from 
analysis (CSF n=8, serum n=7 samples). Given the induction of both peripheral monocytes and 
CNS microglia to activated macrophages, we hypothesized that CSF IL-1β levels represented a 
mixture of CNS derived and peripherally generated IL-1β transported into the CSF.  To express 
the relative contribution of serum IL-1β to measured CSF IL-1β levels, IL-1β ratios were 
calculated by dividing temporally matched CSF/serum samples, and daily ratios were then 
averaged in order to obtain a weekly IL-1β ratio. Significant bivariate associations (p<0.05) were 
analyzed in multivariate models to determine genetic and other variable associations with 
cytokine ratios. 
For those with PTE, Kaplan-Meier analysis was used to examine time to first seizure 
(eight days-three years) by candidate SNP variation while adjusting for time to mortality. IL-1β 
ratios, and SNPs with genotypes that differed significantly in terms PTE risk, were also 
examined using Cox Proportional Hazards models. Cox models were generated with time to first 
seizure (eight days-three years) as the dependent variable and PTE incidence as the event of 
interest. Multivariate Cox models examined either IL-1β ratios or significant SNPs while 
adjusting for covariates significantly associated with PTE status identified in bivariate analysis.  
Cox models were also adjusted for GCS and depressed skull fracture given their documented 
relevance to TBI severity and PTE.  
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3.0  RESULTS 
3.1 POPULATION DESCRIPTION 
3.1.1 IL-1β Genetics Population 
There were 256 adults with moderate-severe TBI and genotype information that otherwise met 
the criteria for PTE analysis. Approximately 81.6 % of the population was men and 18.4% 
women. Mean age was 35.0±0.93yrs. Median GCS score was 6, and mean acute care length of 
stay (LOS) was 22.5±0.68d. The most common mechanisms of injury included automobile 
accidents (50.4%), motorcycle accidents (20.3%), and falls (11.3%). 249 individuals (97.3%) 
were given AEDs for seizure prophylaxis, and PTE developed in 42 individuals (16.4%).  51.2% 
of those with a diagnosis of PTE had at least one EEG obtained at the time of clinical 
presentation. 34.1% of PTE subjects had at least one EEG during acute care, while 70.7% of 
subjects had at least one EEG during the 1wk-3yr post-injury surveillance period. 
A breakdown of the population based on PTE status is provided in Table 1. Individuals 
with a lower ISS score were more likely to develop PTE (p=0.026). IHI status (p=0.033) and 
SDH (p=0.002) were also associated with PTE. Mortality was significantly associated with PTE, 
with those who died having lower PTE incidence. Thus, a mortality adjusted PTE population was 
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created (n=206). There were no differences in injury or demographic information between the 
unadjusted and mortality adjusted PTE populations (data not shown).  
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Table 1. Demographics Table 
 
 12 
3.1.2 IL-1β Level Population 
There were 59 individuals with moderate to severe TBI and acute cytokine information to assess 
factors influencing IL-1β ratios and PTE (Table 1). IHI status was associated with higher IL-1β 
ratios compared to those with more severe extra-cerebral injuries (p=0.047). SDH was also 
associated with higher IL-1β ratios (p=0.037). Lower serum IL-1β levels were associated with 
IHI status (p=0.007) and SDH (p=0.022). Unlike IL-1β ratios, ISS was associated with higher 
serum IL-1β levels (p=0.006).  IL-1β level and ratio (n=46) comparisons to PTE among 
survivors showed no significant differences in injury or demographic information (data not 
shown). 
3.1.3 Healthy Control Population 
Members of the healthy control population were all Caucasian and were 61.5% male (n=8). 
Mean age was 24.62 +/- 11.16 yrs. Sensitivity analyses showed significant differences between 
TBI and control cohorts in regards to age and gender distributions. Given some reports of 
possible sex differences in inflammatory response after TBI,30 we assessed whether or not there 
were differences by sex among controls and found no significant differences in serum (0.361+/-
0.230 women vs. 0.072+/-0.036 men; p=0.257), CSF (0.030+/-0.005 women vs. 0.026+/-0.003 
men; p=0.171), or ratios (0.400+/-0.667 women vs. 0.441+/-0.263 men; p=0.257) IL-1β levels. 
Age was not significantly correlated with IL-1β serum, CSF, or ratio levels among controls 
(p=0.686, 0.733, 0.788, respectively). 
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3.2 ACUTE IL-1Β LEVELS 
Daily and mean weekly CSF and serum IL-1β levels among survivors were compared to healthy 
controls. Daily and mean weekly CSF IL-1β levels for the TBI group were higher than controls 
(p=<0.001 all comparisons) (Figure 1a). CSF/serum IL-1β ratios were higher on d3 post-injury 
(p=0.025), and there was a trend towards higher weekly average levels (p=0.070) compared to 
controls (Figure 1b). Serum IL-1β levels did not differ from controls (Figure 1c). There were no 
significant sex differences in serum (0.377+/-0.543 women vs. 0.550+/-1.719 men; p=0.722), 
CSF (0.088+/-0.109 women vs. 0.123+/-0.167 men; p=0.454), or ratio (0.766+/-0.565 women vs. 
1.699+/-3.771 men; p=0.589) IL-1β weekly average values. 
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 Figure 1. Daily and week 1 mean IL-1β levels (+/- SEM) among survivors (n=46) 
(A) CSF IL-1β levels compared to healthy controls (n=13 controls) (p<0.001 for each time 
point), (B) CSF/Serum IL-1β ratios compared to healthy controls (n=11 controls) (p=0.025 day 
3, and p=0.070 weekly average), (C) Serum IL-1β levels compared to healthy controls (n=11 
controls) (p>0.05 all comparisons). 
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3.3 ACUTE IL-1Β LEVELS AND PTE DEVELOPMENT 
Among survivors, weekly IL-1β ratios were higher in those with PTE vs. No-PTE 
(PTE=3.794±2.274; No-PTE=0.8207±0.1495; p=0.020) (Figure 2a). Serum IL-1β was lower in 
the PTE group (PTE=0.2007±0.1290pg/mL; no-PTE=0.7239±0.3501pg/mL; p=0.016) (Figure 
2b). CSF IL-1β levels were not different between PTE groups (PTE=0.1964±0.0901; no-
PTE=0.0876±0.0159; p=0.864) (Figure 2c). A Cox model, for the IL-1β level population 
described in table 1 and adjusted for time to mortality, ISS, GCS, SDH, and depressed skull 
fracture, showed that higher IL-1β ratios were also associated with increased PTE risk over time 
(Hazard ratio=1.341; CI 1.081-1.665; p=0.008) (Table 2, Figure 3). A similar Cox model 
showed no association between serum IL-1β levels and PTE risk over time (data not shown).  
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Table 2. Cox Proportional Hazard Analysis 
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 Figure 2. Mean IL-1β levels (+/- SEM) over the first week post-injury by PTE status among 
survivors (n=46). 
(A) CSF/Serum IL-1β ratio by PTE (p=0.020), (B) Serum IL-1β levels by PTE (p=0.016), (C) 
CSF IL-1β levels by PTE (p>0.05). 
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 Figure 3. Cox Proportional Hazards cumulative PTE risk based on mean CSF/Serum IL-1β 
ratio. 
Adjusted for time to mortality (in days), age, gender, ISS, GCS, SDH, and depressed skull 
fracture (p=0.008).  
3.4 RS1143634 ASSOCIATION WITH PTE DEVELOPMENT 
Table 3 depicts the overall allelic frequencies for each SNP as well as bivariate associations 
within a mortality adjusted subset of the overall population. There were no significant bivariate 
associations with PTE for rs1143633, rs3136558, rs1143627, and rs16944, regardless of 
mortality adjustment. However, bivariate evaluation showed that rs1143634 was related to PTE 
risk. PTE occurred in 17.6% of individuals with a CC genotype, 47.7% of individuals with a CT 
genotype, and no individuals with a TT genotype (p=0.008). Consistent with previous studies,31 
individuals with the TT genotype (n=13) at rs1143634 comprised only a small percentage of the 
overall population. Grouped genotype analysis revealed that heterozygotes (CT) were at greater 
risk (p=0.005) of developing PTE compared to homozygotes. Kaplan-Meier analysis, adjusting 
for time to mortality, showed that heterozygotes had a shorter time to first seizure compared to 
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homozygotes (CT mean=854.37 days, CI 759.28-949.46; CC+TT mean=1010.51days, CI 
959.40-1061.62; p=0.006). A Cox Proportional Hazards model adjusted for time to mortality, 
age, gender, GCS, ISS, SDH, and depressed skull fracture, showed the CT genotype was 
associated with increased PTE risk over time compared to homozygotes (Hazard ratio=2.845; CI 
1.372-5.900; p=0.005) (Table 2, Figure 4). 
 
Table 3. Bivariate IL-1β Tagging SNP Results 
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 Figure 4. Cox Proportional Hazards cumulative PTE risk based on rs1143634 genotype.  
Adjusted adjusted for time to mortality (in days), age, gender, ISS, GCS, SDH, and depressed 
skull fracture (p=0.005).  
3.5 RS1143634 ASSOCIATIONS WITH IL-1Β LEVELS 
There were no significant bivariate associations with IL-1β ratios, serum, or CSF levels for 
rs1143633, rs1143627, rs3136558, and rs16944 among subjects in the mortality adjusted IL-1β 
level population. Serum IL-1β levels were significantly different (p=0.014) and IL-1β ratios 
showed a trend (p=0.093) based on rs1143634 genotype (Table 2). Grouped genotype analysis 
revealed that CT heterozygotes had lower serum IL-1β levels compared homozygotes (CT 
mean=0.1571±0.0552 pg/mL; CC+TT mean=0.9661±0.5048 pg/mL; p=0.009). Also, CT 
heterozygotes also tended to have higher IL-1β ratios compared to homozygotes (CT 
mean=2.615±1.583; CC+TT mean=0.8251±0.2094; p=0.062).  Rs3136558 also tended to be 
associated (p=0.058) with serum IL-1β levels but further analysis showed a high degree of 
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linkage disequilibrium (LD) between rs3136558 and rs1143634 within our population 
(p=<0.001). 
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4.0  DISCUSSION 
PTE is a significant complication following TBI that leads to increased disability and 
long-term AED treatment. Mechanisms underlying epileptogenesis and PTE are not well 
understood and despite characterized clinical risk factors for PTE, not all patients possessing 
these risk factors go on to develop PTE. Genetic variability, and associated variation in 
biological responses to TBI, may account for increased PTE incidence in certain individuals. The 
most recent Epilepsy Benchmark Research Progress Report lists IL-1β as one potential 
biomarker for epilepsy based on recently published findings.32 Previous work in our lab has 
shown that daily levitiracetam, a widely prescribed AED reduces regional IL-1β expression, 
potentially contributing to its anti-seizure effects in TBI.33 This observation, along with other 
data showing a link between IL-1β and non-traumatic epilepsy,34 provide a rationale for studying 
IL-1β and PTE development. 
IL-1β is produced in the CNS and periphery. In healthy individuals, CNS IL-1β levels are 
very low and beneficial to physiological processes like memory formation and sleep.35 However, 
TBI is associated with increased IL-1β expression,36 which can persist for months post-
injury.37,38 Elevated IL-1β levels are associated with early neuronal death and excitotoxicity,13,14 
suggesting the importance of IL-1β regulation during TBI recovery. Based on these findings, and 
the known pro-convulsant effects of IL-1β, we hypothesized that early TBI induced changes in 
IL-1β levels would be associated with PTE. Given that both blood brain barrier (BBB) disruption 
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and peripheral inflammation occurs with TBI,39 and that CSF IL-1β levels are likely to be a 
product of both CNS and peripheral production, we also explored serum/CSF IL-1β ratios as a 
reflection of the relative contribution of serum IL-1β to CSF IL-1β levels. While our data 
showed CSF IL-1β levels were elevated in our PTE subpopulation, compared to controls, no 
difference in average CSF IL-1β was observed between the PTE and no-PTE groups. Serum IL-
1β levels did not differ from controls. However, serum IL-1β levels were significantly lower in 
the PTE vs. no-PTE group, suggesting relative differences in serum IL-1β transit into the CNS 
between these two groups. Interestingly, individuals with high CSF/serum IL-1β ratios during 
the first week post-injury had significantly higher PTE risk, suggesting that while absolute CSF 
IL-1β are elevated after TBI, the relative contribution of IL-1β from the periphery is the 
measurement most sensitive to eventual PTE development. This association is interesting and 
has implications for early screening, yet further work is needed to determine if/how the serum 
and ratio associations also reflect something about how a persistent peripheral inflammatory 
state, recently characterized over the first year in a clinical population with moderate to severe 
injury,38 may contribute to epileptogenesis and PTE development over the long-term. 
Multivariate Cox models showed that only IL-1β ratios were significantly associated with PTE 
risk overtime, indicating CSF/serum ratios appear to increase the specificity of the contribution 
of peripheral inflammation to CNS pathology.   
Interestingly, type II IL-1 transporters have been implicated in one report with blood to 
brain IL-1β transport across the BBB using an in vitro approach using cerebromicrovascular 
endothelial cells.40 Although clinical TBI studies suggest that some cytokines follow a brain-to-
blood transport gradient,41 similar studies do not identify such a gradient for IL-1β transport.42  
Our results show high serum IL-1β concentrations, relative to CSF, in our cohort with IL-1β 
 24 
levels that are suggestive of a blood-to-brain gradient for IL-1β (figure 1). Additionally, higher 
CSF to serum IL-1β ratios among those with PTE also supports this hypothesis of blood-to-brain 
IL-1β transport (figure 2). This finding, taken with rs11436234 associations with serum levels 
and the ratio, also suggests genetic variation influencing IL-1β transport capacity into the CNS 
over time as a plausible biological mechanism to explore further for how IL-1β pathology 
influences PTE risk.   
Further work is needed to establish why higher IL-1β ratios acutely post-TBI can predict 
PTE onset months to years post-injury. An increased acute inflammatory response might predict 
a prolonged period of chronic (CNS and peripheral) inflammation, and BBB dysfunction that 
contributes to epileptogenesis and PTE. Notably, serum cytokine levels are elevated for at least a 
year after moderate to severe TBI,38 which may contribute to BBB dysfunctional and ongoing 
CNS inflammation. IL-1β induces IL-1β mRNA production in several cell types, including 
activated microglia, resulting in a positive feedback system that may perpetuate CNS 
inflammation over time.43 Interestingly, clinical imaging studies suggest that microglial 
activation can persist for years after TBI and is associated with ongoing white matter 
degeneration.44  Furthermore, studies showing progressive cell death up to a year post-TBI,13 
suggest increases in extracellular ATP associated with apoptosis may chronically activate 
inflammasomes necessary for IL-1β production.10  
Higher acute IL-1β CSF/serum ratios within the PTE group may indicate various long-
term physiological changes, associated with chronic inflammation, which promote 
epileptogenesis. Intraventricular IL-1β infusion can activate both the hypothalamic-pituitary-
adrenal axis and the sympathetic nervous system, decreasing peripheral cellular immune 
responses and resulting in suppressed macrophage IL-1β secretion.45 Thus, individuals with PTE 
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may have acute hyperactivation of this neuroimmunomodulation system resulting in the lower 
serum IL-1β levels as we report in this study.  Studies have also shown increases in IL-1β and/or 
decreases in IL-1 receptor antagonist (IL-1Ra) significantly alters the frequency, duration, and 
threshold of chemical induced seizures.15,46 Additionally, delayed seizure progression has been 
reported in kindling studies that block nerve growth factor (NGF).47 Interestingly, IL-1β up-
regulates NGF both in vitro and in vivo,48,49 and application of IL-1Ra in a TBI rat model 
suppresses NGF-mediated plasticity.50 Further work is needed to discern which, if any, of these 
altered physiological states are reflected by the IL-1β CSF/serum ratio. 
IL-1β gene variant analysis showed a relationship between rs1143634 genotype, PTE, 
and serum IL-1β levels as well as the CSF/serum IL-1β ratio. Individuals with a CT genotype at 
rs1143634 had a significantly increased risk of PTE and those with the CT genotype had a 
significantly shorter time to first seizure (~5 months shorter on average), implicating variability 
at this locus in accelerating epileptogenesis.  Although the minor allele frequency (MAF) for this 
SNP is 0.25, only 13 subjects were TT homozygotes.  Interestingly none of these subjects 
developed PTE. So while this TT subgroup is small and potentially subject to sample bias, the 
data suggests that TT homozygotes are relatively protected against PTE and the CT 
heterozygotes are uniquely the “at risk” group. Further, future validation studies would be 
unlikely to yield a dose response association with PTE risk. 
Heterozygote associations for genetic variation for genes coding membrane receptors can 
occur and may result in multiple actions that affect the phenotype of interest (e.g. differential 
effects of membrane trafficking for receptor protein hetero-dimers vs. homo-dimers).  We have 
previously reported heterozygote associations with PTE for rs10920573 located on the ADORA1 
gene.20 While not a membrane receptor, one might speculate an extracellular milieu with a 
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mixture of different IL-1β isoforms theoretically may have a differential impact on target 
receptor binding, activation, or downstream signaling within inflammation pathways that leads to 
increased PTE risk. As heterozygosity at rs1143634 is also associated with decreased serum IL-
1β, and given that IL-1β can influence BBB permeability, it also stands to reason that IL-1β 
physiology associated heterozygosity at rs1143634 may differentially facilitate serum IL-1β 
transport into the CSF compartment.  Notably, IL-1β modulates expression and efflux 
functionality for BBB carrier transporters like ATP-binding cassette (ABC) transporters,51 for 
which genetic variation may have differential effects on IL-1β levels52 as well as other molecules 
like cortisol,53 in the setting of TBI. Interestingly, ABC transporters also facilitate IL-1β efflux 
from stimulated macrophages,54,55 a function which may be particularly relevant in the context of 
IL-1β contributions from chronically activated microglia44 to PTE development overtime. 
Finally, significant widespread epigenetic modification is known to occur after TBI,56 and given 
previous reports on how epigenetic changes within the IL-1β promoter can occur,57 this may be 
another area for further study regarding mechanisms associated with increased PTE risk with 
rs1143634. 
The rs1143634 SNP is located in a coding region on exon 5 of the IL1β gene, however its 
functionality is still controversial.58 Studies suggest that the T allele is associated with increased 
IL-1β production,52 while others found no difference in IL-1β secretion.59 Rs1143634 tags 
approximately a 1Kb region of the IL-1β gene, located on chromosome 2, that also contains 
missense SNPs rs141525736, rs139843362, and rs114640380 (HapMap phase 3; hapmap.org). 
However, these SNPs are not highly variable, and no literature exists regarding their 
functionality.  Also, it is unclear where LD decays for the region tagged by rs1143634, thus 
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additional genotyping around the DNA block representing rs1143634 may be helpful to better 
understand the functional implications of variation, including heterozygosity, at this locus.  
ISS, IHI, and SDH were all linked to PTE. Individuals with lower ISS, an IHI, or a 
subdural hematoma were more likely to develop PTE. As ISS is a measure of global, anatomical 
injury severity, it is not surprising that individuals with an IHI also have lower ISS. However, 
ISS/IHI were not significant predictors of PTE in multivariate analysis. Our findings do support 
previous studies showing SDH can increase PTE risk.2   
Despite the promising findings linking IL-1β and PTE, some limitations should be 
considered.  Medical record data abstraction makes it difficult to accurately assess recurrent 
seizures and PTE severity. As such, recurrent seizures were not tracked.  Also, subclinical or 
non-convulsive seizures occurring in subjects still intubated and sedated beyond the first week 
post-injury may have been missed.  The sample was limited to Caucasians with moderate to 
severe injury, limiting the generalizability to those with different racial backgrounds. Also, the 
overall sample size is modest for a genetic association study.  However, the cohort available for 
biomarker and genetic analysis used is one of the largest moderate to severe TBI cohorts 
currently available.  Nonetheless, to our knowledge, this is the first research report implicating 
serum IL-1β contributions to CSF IL-1β levels and also genetic variability in the IL-1B gene 
with PTE. Further work is needed to replicate these findings in independent populations and 
better understand the mechanistic implications associated with these relationships.  If validated, 
the findings might stimulate further research testing agents that target IL-1β to prevent and treat 
PTE.  If validated, the findings might also support future work assessing the utility of genetic 
screening paradigms, paired with EEG screening and clinical care pathways, which result in risk 
stratified treatment and prevention protocols for PTE. Additionally, future work exploring 
 28 
genetic variation and levels for other biomarkers relevant to TBI induced inflammation and PTE 
development is warranted.   
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